Overview

Aprepitant for Prevention of Postoperative Nausea and Vomiting in Elective Hysterectomy

Status:
Terminated
Trial end date:
2011-10-01
Target enrollment:
Participant gender:
Summary
The purpose of the study is to determine whether 40 mg aprepitant administered before surgery is effective for preventing vomiting in the first 24 hours after surgery in women undergoing elective hysterectomy.
Phase:
Phase 4
Details
Lead Sponsor:
Mayo Clinic
Treatments:
Aprepitant
Fosaprepitant